Brief: IO Biotech Completes Enrollment of 380 Patients in Pivotal Phase 3 Trial in Advanced Melanoma

IO Biotech

10/11/2023 13:12

Nov 10 (Reuters) - IO Biotech Inc  IOBT.O :
    * IO BIOTECH COMPLETES ENROLLMENT OF 380 PATIENTS IN PIVOTAL
PHASE
3 TRIAL IN ADVANCED MELANOMA
    * IO BIOTECH COMPLETES ENROLLMENT OF 380 PATIENTS IN PIVOTAL
PHASE
3 TRIAL IN ADVANCED MELANOMA
    * IO BIOTECH INC- TRIAL EXPECTED TO REACH PRIMARY ENDPOINT
OF
PROGRESSION FREE SURVIVAL IN SECOND HALF OF 2025
    * IO BIOTECH INC- PER-PROTOCOL INTERIM ANALYSIS EXPECTED IN
MID-2024

Source text for Eikon:  ID:nGNX5sblBg 
Further company coverage:  IOBT.O 

 ((Reuters.Briefs@thomsonreuters.com;))